Research graph
References from Lenalidomide triggers ferroptosis in multiple myeloma by blocking the c-Maf/USP7 signaling pathway to induce the ubiquitination and degradation of FTH1. Local targets link to admitted publications; unresolved targets remain external evidence.
Multiple myeloma
10.1038/s41572-024-00529-7 · 2024 · External reference
New prognostic systems for multiple myeloma in the context of contemporary therapies
10.1182/blood.2024023841 · 2025 · External reference
New horizons in our understanding of precursor multiple myeloma and early interception
10.1038/s41568-024-00755-x · 2024 · External reference
New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma
10.1158/1078-0432.ccr-16-0184 · 2016 · External reference
Immune-based therapies in the management of multiple myeloma
10.1038/s41408-020-00350-x · 2020 · External reference
New biological therapies for multiple myeloma
10.1146/annurev-med-050522-033815 · 2024 · External reference
Integrating immune therapies for the treatment of multiple myeloma
10.6004/jnccn.2023.7100 · 2023 · External reference
Bispecific antibodies in the treatment of multiple myeloma
10.1038/s41408-024-01139-y · 2024 · External reference
CAR-T cell therapy for cancer: current challenges and future directions
10.1038/s41392-025-02269-w · 2025 · External reference
CAR-T cell therapy in multiple myeloma: current status and future challenges
10.1038/s41408-024-01191-8 · 2024 · External reference
Potential future direction of measurable residual disease evaluation in multiple myeloma
10.1182/blood.2023020284 · 2023 · External reference
Bone marrow inflammation in haematological malignancies
10.1038/s41577-024-01003-x · 2024 · External reference
The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
10.1038/s41375-025-02677-5 · 2025 · External reference
Circulating biosignatures in multiple myeloma and their role in multidrug resistance
10.1186/s12943-022-01683-w · 2023 · External reference
Recommendations for robust and reproducible research on ferroptosis
10.1038/s41580-025-00843-2 · 2025 · External reference
The cell biology of ferroptosis
10.1038/s41580-024-00703-5 · 2024 · External reference
Cell death
10.1016/j.cell.2023.11.044 · 2024 · External reference
A guide to cell death pathways
10.1038/s41580-023-00689-6 · 2024 · External reference
The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions
10.1016/j.ccell.2024.03.011 · 2024 · External reference
Ferroptotic therapy in cancer: benefits, side effects, and risks
10.1186/s12943-024-01999-9 · 2024 · External reference
Research Progress on Ferroptosis in multiple myeloma
10.1007/s11864-024-01250-z · 2024 · External reference
Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis
10.1007/s10495-023-01909-2 · 2024 · External reference
DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis
10.1007/s10238-025-01673-4 · 2025 · External reference
Mechanisms controlling cellular and systemic iron homeostasis
10.1038/s41580-023-00648-1 · 2024 · External reference
Targeting Ferroptosis to Iron out Cancer
10.1016/j.ccell.2019.04.002 · 2019 · External reference
The role and regulation of Maf proteins in cancer
10.1186/s40364-023-00457-w · 2023 · External reference
MAFB: a key regulator of myeloid commitment involved in hematological diseases
10.1038/s41420-025-02551-4 · 2025 · External reference
Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma
10.1016/j.canlet.2022.215791 · 2022 · External reference
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
10.1182/blood-2016-03-706077 · 2016 · External reference
GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target
10.1038/bcj.2013.67 · 2014 · External reference
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells
10.1126/science.1244851 · 2014 · External reference
Lenalidomide induces degradation of IKZF1 and IKZF3
10.4161/21624011.2014.941742 · 2014 · External reference
Mechanism of action of lenalidomide in hematological malignancies
10.1186/1756-8722-2-36 · 2009 · External reference
Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study
10.1212/wnl.0000000000003093 · 2016 · External reference
MUC1-C is a target in lenalidomide resistant multiple myeloma
10.1111/bjh.14801 · 2017 · External reference
Multiple myeloma
10.1016/s0140-6736(21)00135-5 · 2021 · External reference
ARK5 is transcriptionally regulated by the large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma
10.1038/sj.onc.1208844 · 2005 · External reference
The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival
10.1074/jbc.ra119.010724 · 2020 · External reference
Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis
10.1038/s41401-019-0249-1 · 2019 · External reference
Targeting ferroptosis as a vulnerability in cancer
10.1038/s41568-022-00459-0 · 2022 · External reference
Ferroptosis: when metabolism meets cell death
10.1152/physrev.00031.2024 · 2025 · External reference
Exploiting ferroptosis vulnerabilities in cancer
10.1038/s41556-024-01425-8 · 2024 · External reference
Iron metabolism and ferroptosis in human health and disease
10.1186/s12915-025-02378-6 · 2025 · External reference
Ironing out the details of ferroptosis
10.1038/s41556-024-01361-7 · 2024 · External reference
Ferroptosis: a regulated cell death Nexus linking metabolism, redox biology, and disease
10.1016/j.cell.2017.09.021 · 2017 · External reference
Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1
10.1016/j.apsb.2021.03.036 · 2021 · External reference
Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: a therapeutic strategy for triple-negative breast cancer
2025 · External reference
Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/miR-19b-3p/FTH1 axis
2022 · External reference
Structural basis for the intracellular regulation of ferritin degradation
10.1038/s41467-024-48151-1 · 2024 · External reference
Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy
10.1038/nature13148 · 2014 · External reference
Polyphyllin B suppresses gastric tumor growth by modulating Iron metabolism and inducing Ferroptosis
10.7150/ijbs.80324 · 2023 · External reference
Sodium butyrate induces ferroptosis in colorectal cancer cells by promoting NCOA4-FTH1-mediated ferritinophagy
10.1016/j.intimp.2025.115188 · 2025 · External reference
Artesunate induces ferroptosis in osteosarcoma through NCOA4-mediated ferritinophagy
10.1096/fj.202403160r · 2025 · External reference
Heme oxygenase-1 (HO-1) depletion promotes ferroptosis to reverse cisplatin-resistance via enhancing NCOA4-mediated ferritinophagy in ovarian cancer
2025 · External reference
DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis
10.1007/s10238-025-01673-4 · ExternalCitation · doi-reference
Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis
10.1007/s10495-023-01909-2 · ExternalCitation · doi-reference
Research Progress on Ferroptosis in multiple myeloma
10.1007/s11864-024-01250-z · ExternalCitation · doi-reference
Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1
10.1016/j.apsb.2021.03.036 · ExternalCitation · doi-reference
Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma
10.1016/j.canlet.2022.215791 · ExternalCitation · doi-reference
Targeting Ferroptosis to Iron out Cancer
10.1016/j.ccell.2019.04.002 · ExternalCitation · doi-reference
The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions
10.1016/j.ccell.2024.03.011 · ExternalCitation · doi-reference
Ferroptosis: a regulated cell death Nexus linking metabolism, redox biology, and disease
10.1016/j.cell.2017.09.021 · ExternalCitation · doi-reference
Cell death
10.1016/j.cell.2023.11.044 · ExternalCitation · doi-reference
Sodium butyrate induces ferroptosis in colorectal cancer cells by promoting NCOA4-FTH1-mediated ferritinophagy
10.1016/j.intimp.2025.115188 · ExternalCitation · doi-reference
Multiple myeloma
10.1016/s0140-6736(21)00135-5 · ExternalCitation · doi-reference
GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target
10.1038/bcj.2013.67 · ExternalCitation · doi-reference
Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy
10.1038/nature13148 · ExternalCitation · doi-reference
The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
10.1038/s41375-025-02677-5 · ExternalCitation · doi-reference
CAR-T cell therapy for cancer: current challenges and future directions
10.1038/s41392-025-02269-w · ExternalCitation · doi-reference
Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis
10.1038/s41401-019-0249-1 · ExternalCitation · doi-reference
Immune-based therapies in the management of multiple myeloma
10.1038/s41408-020-00350-x · ExternalCitation · doi-reference
Bispecific antibodies in the treatment of multiple myeloma
10.1038/s41408-024-01139-y · ExternalCitation · doi-reference
CAR-T cell therapy in multiple myeloma: current status and future challenges
10.1038/s41408-024-01191-8 · ExternalCitation · doi-reference
MAFB: a key regulator of myeloid commitment involved in hematological diseases
10.1038/s41420-025-02551-4 · ExternalCitation · doi-reference
Structural basis for the intracellular regulation of ferritin degradation
10.1038/s41467-024-48151-1 · ExternalCitation · doi-reference
Ironing out the details of ferroptosis
10.1038/s41556-024-01361-7 · ExternalCitation · doi-reference
Exploiting ferroptosis vulnerabilities in cancer
10.1038/s41556-024-01425-8 · ExternalCitation · doi-reference
Targeting ferroptosis as a vulnerability in cancer
10.1038/s41568-022-00459-0 · ExternalCitation · doi-reference
New horizons in our understanding of precursor multiple myeloma and early interception
10.1038/s41568-024-00755-x · ExternalCitation · doi-reference
Multiple myeloma
10.1038/s41572-024-00529-7 · ExternalCitation · doi-reference
Bone marrow inflammation in haematological malignancies
10.1038/s41577-024-01003-x · ExternalCitation · doi-reference
Mechanisms controlling cellular and systemic iron homeostasis
10.1038/s41580-023-00648-1 · ExternalCitation · doi-reference
A guide to cell death pathways
10.1038/s41580-023-00689-6 · ExternalCitation · doi-reference
The cell biology of ferroptosis
10.1038/s41580-024-00703-5 · ExternalCitation · doi-reference
Recommendations for robust and reproducible research on ferroptosis
10.1038/s41580-025-00843-2 · ExternalCitation · doi-reference
ARK5 is transcriptionally regulated by the large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma
10.1038/sj.onc.1208844 · ExternalCitation · doi-reference
The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival
10.1074/jbc.ra119.010724 · ExternalCitation · doi-reference
Artesunate induces ferroptosis in osteosarcoma through NCOA4-mediated ferritinophagy
10.1096/fj.202403160r · ExternalCitation · doi-reference
MUC1-C is a target in lenalidomide resistant multiple myeloma
10.1111/bjh.14801 · ExternalCitation · doi-reference
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells
10.1126/science.1244851 · ExternalCitation · doi-reference
New biological therapies for multiple myeloma
10.1146/annurev-med-050522-033815 · ExternalCitation · doi-reference
Ferroptosis: when metabolism meets cell death
10.1152/physrev.00031.2024 · ExternalCitation · doi-reference
New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma
10.1158/1078-0432.ccr-16-0184 · ExternalCitation · doi-reference
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
10.1182/blood-2016-03-706077 · ExternalCitation · doi-reference
Potential future direction of measurable residual disease evaluation in multiple myeloma
10.1182/blood.2023020284 · ExternalCitation · doi-reference
New prognostic systems for multiple myeloma in the context of contemporary therapies
10.1182/blood.2024023841 · ExternalCitation · doi-reference
Mechanism of action of lenalidomide in hematological malignancies
10.1186/1756-8722-2-36 · ExternalCitation · doi-reference
Iron metabolism and ferroptosis in human health and disease
10.1186/s12915-025-02378-6 · ExternalCitation · doi-reference
Circulating biosignatures in multiple myeloma and their role in multidrug resistance
10.1186/s12943-022-01683-w · ExternalCitation · doi-reference
Ferroptotic therapy in cancer: benefits, side effects, and risks
10.1186/s12943-024-01999-9 · ExternalCitation · doi-reference
The role and regulation of Maf proteins in cancer
10.1186/s40364-023-00457-w · ExternalCitation · doi-reference
Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study
10.1212/wnl.0000000000003093 · ExternalCitation · doi-reference
Lenalidomide induces degradation of IKZF1 and IKZF3
10.4161/21624011.2014.941742 · ExternalCitation · doi-reference
Integrating immune therapies for the treatment of multiple myeloma
10.6004/jnccn.2023.7100 · ExternalCitation · doi-reference
Polyphyllin B suppresses gastric tumor growth by modulating Iron metabolism and inducing Ferroptosis
10.7150/ijbs.80324 · ExternalCitation · doi-reference
